Evidence suggests that PD-L1-positive NSCLC patients treated with ICIs who have stromal CD8+ effector T cells as the most abundant TIL subpopulation experience better outcomes (Table 6). The gene discussed is CD8A; the disease is non-small cell lung carcinoma.